Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Alessandro Leonetti, Francesco Leonardi, Melissa Bersanelli & Sebastiano Buti. (2017) Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma. Therapeutics and Clinical Risk Management 13, pages 799-806.
Read now
Read now
Martin G. Klatt, Daniel J. Kowalewski, Heiko Schuster, Moreno Di Marco, Jörg Hennenlotter, Arnulf Stenzl, Hans-Georg Rammensee & Stefan Stevanović. (2016) Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design. OncoImmunology 5:8.
Read now
Read now
Articles from other publishers (15)
Yu-Wei Hao, Yun Zhang, Hui-Ping Guo, Wei Xu, Xu Bai, Jian Zhao, Xiao-Hui Ding, Sheng Gao, Meng-Qiu Cui, Bai-Chuan Liu, Hui-Yi Ye & Hai-Yi Wang. (2023) Differentiation between renal epithelioid angiomyolipoma and clear cell renal cell carcinoma using clear cell likelihood score. Abdominal Radiology 48:12, pages 3714-3727.
Crossref
Crossref
Yohei Sekino, Jun Teishima, Gangning Liang & Nobuyuki Hinata. (2022) Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma. International Journal of Urology 29:12, pages 1419-1428.
Crossref
Crossref
L. Hamieh, R. L. Beck, V. H. Le & J. J. Hsieh. (2020) The efficacy of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma exhibiting primary resistance to front-line targeted therapy or immunotherapy. Cancer Urology 16:3, pages 53-61.
Crossref
Crossref
Lana Hamieh, Rachel L. Beck, Valerie H. Le & James J. Hsieh. (2020) The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy. Clinical Genitourinary Cancer 18:4, pages 252-257.e2.
Crossref
Crossref
Hassan Dianat-Moghadam & Ladan Teimoori-Toolabi. (2019) Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications. Current Drug Targets 20:8, pages 852-870.
Crossref
Crossref
Viktor Grünwald, Thomas Powles, Toni K Choueiri, Thomas E Hutson, Camillo Porta, Masatoshi Eto, Cora N Sternberg, Sun Young Rha, Cixin S He, Corina E Dutcus, Alan Smith, Lea Dutta, Kalgi Mody & Robert J Motzer. (2019) Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. Future Oncology 15:9, pages 929-941.
Crossref
Crossref
Kevin Zarrabi, Chunhui Fang & Shenhong Wu. (2017) New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy. Journal of Hematology & Oncology 10:1.
Crossref
Crossref
Victoria Tovar, Helena Cornella, Agrin Moeini, Samuel Vidal, Yujin Hoshida, Daniela Sia, Judit Peix, Laia Cabellos, Clara Alsinet, Sara Torrecilla, Iris Martinez-Quetglas, Juan José Lozano, Christèle Desbois-Mouthon, Manel Solé, Josep Domingo-Domenech, Augusto Villanueva & Josep M Llovet. (2017) Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. Gut 66:3, pages 530-540.
Crossref
Crossref
Bernhard Englinger, Daniela Lötsch, Christine Pirker, Thomas Mohr, Sushilla van Schoonhoven, Bernd Boidol, Charles-Hugues Lardeau, Melanie Spitzwieser, Pál Szabó, Petra Heffeter, Irene Lang, Margit Cichna-Markl, Bettina Grasl-Kraupp, Brigitte Marian, Michael Grusch, Stefan Kubicek, Gergely Szakács & Walter Berger. (2016) Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression. Oncotarget 7:31, pages 50161-50179.
Crossref
Crossref
Matsui Junji. (2016) Lenvatinib Suppresses Angiogenesis through the Inhibition of both the VEGFR and FGFR Signaling Pathways. Global Journal of Cancer Therapy, pages 019-025.
Crossref
Crossref
Jennifer J. Wheler, Filip Janku, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel Karp, Gerald S. Falchook, Apostolia M. Tsimberidou, Sarina Piha-Paul, Roosevelt Anderson, Danxia Ke, Vincent Miller, Roman Yelensky, J. Jack Lee, David S. Hong & Razelle Kurzrock. (2016) Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Research 76:13, pages 3690-3701.
Crossref
Crossref
Robert J Motzer, Thomas E Hutson, Hilary Glen, M Dror Michaelson, Ana Molina, Timothy Eisen, Jacek Jassem, Jakub Zolnierek, Jose Pablo Maroto, Begoña Mellado, Bohuslav Melichar, Jiri Tomasek, Alton Kremer, Han-Joo Kim, Karen Wood, Corina Dutcus & James Larkin. (2015) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. The Lancet Oncology 16:15, pages 1473-1482.
Crossref
Crossref
Joshua C. Anderson, Christopher D. Willey, Amitkumar Mehta, Karim Welaya, Dongquan Chen, Christine W. Duarte, Pooja Ghatalia, Waleed Arafat, Ankit Madan, Sunil Sudarshan, Gurudatta Naik, William E. Grizzle, Toni K. Choueiri & Guru Sonpavde. (2015) High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes. PLOS ONE 10:9, pages e0139267.
Crossref
Crossref
Yujie Zhao & Alex A. Adjei. (2015) Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. The Oncologist 20:6, pages 660-673.
Crossref
Crossref
Chih-Hung Lin, Vincent Dammai, Boris Adryan & Tien Hsu. (2014) Interaction between Nm23 and the tumor suppressor VHL. Naunyn-Schmiedeberg's Archives of Pharmacology 388:2, pages 143-152.
Crossref
Crossref